Oppenheimer Asset Management’s Takeda Pharmaceutical TAK Stock Holding History

Oppenheimer Asset Management’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.02M	Sell	63,829 -570	-0.9%	-$9.43K	0.01%	738
2026 Q1	$1.19M	Buy	64,399 +6,125	+11%	+$107K	0.01%	680
2025 Q4	$908K	Buy	58,274 +294	+0.5%	+$4.2K	0.01%	697
2025 Q3	$849K	Buy	57,980 +367	+0.6%	+$5.45K	0.01%	796
2025 Q2	$891K	Buy	57,613 +2,147	+4%	+$31.7K	0.01%	768
2025 Q1	$825K	Sell	55,466 -3,585	-6%	-$50.2K	0.01%	760
2024 Q4	$782K	Sell	59,051 -138,148	-70%	-$1.9M	0.01%	779
2024 Q3	$2.8M	Sell	197,199 -56,430	-22%	-$800K	0.03%	457
2024 Q2	$3.28M	Buy	253,629 +22,979	+10%	+$304K	0.04%	407
2024 Q1	$3.2M	Buy	230,650 +13,586	+6%	+$198K	0.05%	367
2023 Q4	$3.1M	Sell	217,064 -26,521	-11%	-$376K	0.04%	406
2023 Q3	$3.77M	Sell	243,585 -6,175	-2%	-$95.6K	0.06%	338
2023 Q2	$3.92M	Sell	249,760 -4,120	-2%	-$67.5K	0.06%	336
2023 Q1	$4.18M	Sell	253,880 -9,538	-4%	-$152K	0.06%	304
2022 Q4	$4.11M	Sell	263,418 -30,548	-10%	-$427K	0.07%	310
2022 Q3	$3.81M	Sell	293,966 -1,044	-0.4%	-$14.5K	0.07%	293
2022 Q2	$4.14M	Sell	295,010 -15,440	-5%	-$220K	0.07%	293
2022 Q1	$4.45M	Buy	310,450 +21,926	+8%	+$322K	0.06%	317
2021 Q4	$3.93M	Sell	288,524 -131,993	-31%	-$1.85M	0.05%	359
2021 Q3	$6.89M	Sell	420,517 -21,490	-5%	-$361K	0.1%	243
2021 Q2	$7.44M	Buy	442,007 +62,104	+16%	+$1.06M	0.11%	224
2021 Q1	$6.94M	Buy	379,903 +33,858	+10%	+$609K	0.11%	220
2020 Q4	$6.3M	Buy	346,045 +25,302	+8%	+$444K	0.11%	230
2020 Q3	$5.72M	Sell	320,743 -8,478	-3%	-$154K	0.11%	214
2020 Q2	$5.9M	Sell	329,221 -62,667	-16%	-$1.13M	0.12%	201
2020 Q1	$5.95M	Sell	391,888 -34,914	-8%	-$633K	0.15%	168
2019 Q4	$8.42M	Sell	426,802 -19,047	-4%	-$364K	0.18%	140
2019 Q3	$7.67M	Buy	445,849 +7,825	+2%	+$135K	0.17%	152
2019 Q2	$7.75M	Buy	438,024 +53,616	+14%	+$976K	0.17%	146
2019 Q1	$7.83M	Buy	384,408 +74,247	+24%	+$1.49M	0.18%	146
2018 Q4	$5.22M	Buy	+310,161	New	+$5.24M	0.13%	190

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Oppenheimer Asset Management's TAK Position: Q2 2026 in Review

Oppenheimer Asset Management reduced its Takeda Pharmaceutical (TAK) stake by 0.89% in Q2 2026, selling an estimated $9.43K and leaving 63,829 shares worth $1.02M. The position accounts for 0.01% of the portfolio, ranked #738.

Oppenheimer Asset Management first reported a position in TAK in Q4 2018 and has held it in 31 quarters since. The position peaked at $8.42M in Q4 2019. 376 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

Oppenheimer Asset Management held 63,829 shares of Takeda Pharmaceutical worth $1.02M as of Q2 2026.
Oppenheimer Asset Management sold 570 Takeda Pharmaceutical shares in Q2 2026, an estimated $9.43K.
Takeda Pharmaceutical made up 0.01% of Oppenheimer Asset Management's portfolio in Q2 2026, its #738 holding.
Oppenheimer Asset Management first reported a position in Takeda Pharmaceutical in Q4 2018 and has held it in 31 quarters since.
Oppenheimer Asset Management's Takeda Pharmaceutical position peaked at $8.42M in Q4 2019.
376 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on Oppenheimer Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.